During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up with news.If you are looking to day trade also check out my Top 2011 Stock Gainers , Stocks to Buy 2012.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have technical analysis different stocks-Right Here. Market Technical analysis Right Here
Quick Look Market Closing Price:
At the close: Dow +0.34% to 12983. S&P +0.43% to 1363. Nasdaq +0.81% to 2957.
Treasurys: 30-year +0.15%. 10-yr +0.08%. 5-yr -0.02%.
Commodities: Crude +1.75% to $108.14. Gold +0.55% to $1781.05.
Currencies: Euro +0.91% vs. dollar. Yen -0.45%. Pound -0.41%.
After Hours News:
OmniVision Technologies (OVTI): FQ3 EPS of $0.13 in-line. Revenue of $185.2M (-15% Y/Y) beats by $6.3M. Company expects FQ4 revenue of $195M-$215M and EPS of $0.15-$0.28, above a consensus of $170.7M and $0.10. Shares +14% AH.
Salesforce.com (CRM): FQ4 EPS of $0.43 beats by $0.03. Revenue of $631.9M (+38% Y/Y) beats by $7.9M. Company expects FQ1 EPS of $0.33-$0.34, below $0.36 consensus. Expects FY13 EPS of $1.58-$1.62, largely below $1.62 consensus. Though EPS guidance is light, the company expects FQ1 revenue of $673M-$678M and 2012 revenue of $2.92B-$2.95B, above estimates of $663.1M and $2.91B. Deferred revenue reached $1.38B, +48% Y/Y and soothing concerns about slowing growth. Unbilled deferred revenue +47% to $2.2B. Sales & marketing expenses +40% to $327.6M. Free cash flow was $195.7M, well above net income of $61.6M. CRM +8.1% AH
Chelsea Therapeutics (CHTP) +58.5% AH after the FDA's cardiovascular and renal drugs advisory committee votes 7-4 to recommend the approval of Chelsea's Northera drug. The FDA is set to make a final decision on Northera by March 28
Century Aluminum (CENX): Q4 EPS of -$0.35 may not be comparable to consensus of -$0.32. Revenue of $318M (+0.4% Y/Y) in-line.
Molycorp (MCP): Q4 EPS of $0.41 beats by $0.01. Revenue of $132.9M (+512% Y/Y) misses by $3M. Gross margin of 52.9% fell 680 bps Q/Q, mostly due to higher raw material and chemical costs. The company is reiterating guidance for 2012 production of 8K-10K metric tons of rare-earth oxide (REO) equivalents. It sees its per-kilogram production costs increasing slightly in 2012 due to Project Phoenix start-up costs, but normalizing in 2013. MCP -0.6% AH,
Monster Worldwide (MNST): Q4 EPS of $0.35 misses by $0.02. Revenue of $410M (+28.5% Y/Y) in-line. Shares -5.6% AH.
Deckers Outdoor (DECK): Q4 EPS of $3.18 beats by $0.05. Revenue of $603.9M (+40.4% Y/Y) beats by $38M..Deckers' Q4: Deckers is guiding for Q1 revenue growth of just 19% Y/Y, and an EPS decline of 50%. Current estimates are for 28.5% revenue growth, and 29% EPS growth. In addition, Deckers expects 2012 revenue growth of 15%, and EPS to be roughly flat with 2011 levels, with higher sheepskin costs pressuring earnings. The Street expects 19% revenue growth and 14% EPS growth. A $100M stock buyback has been authorized. DECK -10.3% AH.
Crocs (CROX): Q4 EPS of $0.06 beats by $0.02. Revenue of $203M (+14% Y/Y) misses by $2M. Shares -5% AH
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
